On December 18, 2025 MiraDx, a molecular diagnostics company focused on germline genetic testing to personalize cancer treatment, reported a new analysis has been published in the Journal of Health Economics and Outcomes Research demonstrating that the PROSTOX ultra test can deliver substantial long-term economic and quality-of-life benefits for patients and the healthcare system.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PROSTOX ultra is a clinically validated germline genetic test for men with localized prostate cancer considering stereotactic body radiation therapy (SBRT), a treatment that delivers high doses of radiation over a short time period, with 5-7 treatments. The test identifies patients at higher risk of developing late genitourinary (GU) toxicity—urinary side effects such as urgency, leakage, or discomfort that may occur after treatment. While SBRT is a very effective and convenient treatment for prostate cancer, a subset of patients experience urinary side effects that present months or even years after treatment and can persist throughout the patient’s lifetime. By identifying patients with increased risk of these side effects from SBRT, PROSTOX ultra helps doctors and patients make more informed treatment decisions and consider alternative options when needed.
The study, which modeled clinical pathways incorporating PROSTOX ultra versus treatment guided by the current standard of care for patients receiving treatment for localized prostate cancer, found a significant cost savings of $19,615 per tested patient. Over a lifetime, the benefits grow even larger. The analysis showed that each patient tested with PROSTOX ultra is expected to save the health care system approximately $24,777 over the patient’s lifetime, while also gaining 0.24 additional quality-adjusted life years (QALYs) compared to patients evaluated without genetic risk assessment.
The publication, "Economic Evaluation of a Novel MicroRNA-Based Assay to Determine Risk of Late Genitourinary Radiation Toxicity in Patients With Prostate Cancer," can be viewed in its entirety by visiting the Journal of Health Economics and Outcomes Research website here: View Source
"Physicians in practice using PROSTOX ultra are seeing its benefits in helping their patients avoid late GU toxicity from SBRT. These new results also now show that PROSTOX ultra meaningfully reduces the long-term cost burden on the healthcare system," said Melissa Stoppler, MD, Executive Vice President of Medical Affairs at MiraDx. "This new evidence further validates the value of integrating the test into treatment considerations for localized prostate cancer."
(Press release, MiraDx, DEC 18, 2025, View Source [SID1234661547])